Arcturus Therapeutics (ARCT) Competitors $20.26 -0.77 (-3.66%) Closing price 04:00 PM EasternExtended Trading$20.90 +0.63 (+3.13%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. DYN, HRMY, IMCR, APGE, SRPT, AUPH, CDTX, VCEL, PAHC, and ARDXShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Dyne Therapeutics (DYN), Harmony Biosciences (HRMY), Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Vericel (VCEL), Phibro Animal Health (PAHC), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors Dyne Therapeutics Harmony Biosciences Immunocore Apogee Therapeutics Sarepta Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Vericel Phibro Animal Health Ardelyx Dyne Therapeutics (NASDAQ:DYN) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations. Do analysts rate DYN or ARCT? Dyne Therapeutics presently has a consensus price target of $34.07, suggesting a potential upside of 158.28%. Arcturus Therapeutics has a consensus price target of $50.57, suggesting a potential upside of 149.61%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, DYN or ARCT? Dyne Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Do insiders and institutionals believe in DYN or ARCT? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, DYN or ARCT? Arcturus Therapeutics has higher revenue and earnings than Dyne Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.42Arcturus Therapeutics$152.31M3.61-$80.94M-$2.23-9.09 Is DYN or ARCT more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. Arcturus Therapeutics' return on equity of -24.87% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% Arcturus Therapeutics -49.26%-24.87%-17.75% Does the media favor DYN or ARCT? In the previous week, Arcturus Therapeutics had 5 more articles in the media than Dyne Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 0 mentions for Dyne Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.75 beat Dyne Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dyne Therapeutics Neutral Arcturus Therapeutics Positive SummaryDyne Therapeutics and Arcturus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$550.26M$3.13B$5.73B$10.43BDividend YieldN/A2.36%5.61%4.58%P/E Ratio-9.0921.0476.4226.62Price / Sales3.61448.77551.00126.98Price / CashN/A44.8325.8131.15Price / Book2.289.7813.626.47Net Income-$80.94M-$52.73M$3.29B$271.57M7 Day Performance12.00%2.40%1.67%2.83%1 Month Performance9.45%4.69%4.04%7.27%1 Year Performance-4.21%16.28%80.70%26.07% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.7931 of 5 stars$20.26-3.7%$50.57+149.6%+2.0%$550.26M$152.31M-9.09180DYNDyne Therapeutics3.3789 of 5 stars$12.86-2.2%$34.07+164.9%-63.3%$1.87BN/A-3.33100HRMYHarmony Biosciences4.5385 of 5 stars$32.50+0.3%$51.00+56.9%-17.5%$1.86B$714.73M10.48200Positive NewsAnalyst UpgradeIMCRImmunocore2.1143 of 5 stars$34.42-2.3%$56.89+65.3%0.0%$1.78B$310.20M-86.05320APGEApogee Therapeutics2.2275 of 5 stars$36.86-0.1%$97.29+163.9%-35.0%$1.70BN/A-8.9291SRPTSarepta Therapeutics4.3675 of 5 stars$17.47+0.5%$39.32+125.1%-85.3%$1.70B$1.90B-20.081,372Analyst UpgradeAUPHAurinia Pharmaceuticals2.7719 of 5 stars$12.81+0.5%$12.00-6.3%+81.5%$1.68B$235.13M29.79300Positive NewsCDTXCidara Therapeutics3.3301 of 5 stars$66.91+2.0%$64.14-4.1%+569.7%$1.66B$1.27M-6.0190News CoverageAnalyst ForecastHigh Trading VolumeVCELVericel2.8502 of 5 stars$31.42-2.4%$60.40+92.2%-31.7%$1.62B$237.22M261.86300PAHCPhibro Animal Health4.5433 of 5 stars$39.53-0.2%$28.40-28.2%+72.4%$1.61B$1.30B33.502,475Positive NewsInsider TradeARDXArdelyx4.2607 of 5 stars$6.53-1.2%$11.70+79.2%+1.5%$1.59B$333.61M-28.3990 Related Companies and Tools Related Companies Dyne Therapeutics Alternatives Harmony Biosciences Alternatives Immunocore Alternatives Apogee Therapeutics Alternatives Sarepta Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Cidara Therapeutics Alternatives Vericel Alternatives Phibro Animal Health Alternatives Ardelyx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts